Cellusion is a biotechnology research firm that focuses on corneal endothelial regenerative medicine intended to improve eye vision.
Cellusion has raised $20.3M in total funding. The most recent round was Series C. The last funding was announced in June 2023.
Cellusion's investors include Nissay Capital, JIC Venture Growth Investments, SMBC Venture Capital, UTEC - The University of Tokyo Edge Capital Partners, Keio Innovation Initiative.
Cellusion is headquartered in Tokyo, Japan.
Cellusion is a biotechnology research firm that focuses on corneal endothelial regenerative medicine intended to improve eye vision.
Cellusion is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cellusion — Funding & Investors." VCBacked, June 6, 2023, https://www.vcbacked.co/company/cellusion. Accessed August 14, 2026.
VCBacked. (2023). Cellusion — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/cellusion
{{cite web |title=Cellusion — Funding & Investors |url=https://www.vcbacked.co/company/cellusion |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated